Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 44 for “"imatinib"”.
-
Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib
Imatinib is a first line therapy for the treatment of chronic myeloid leukaemia (CML). Treatment with imatinib must be continuous and indefinite for most patients to maintain disease control. Despite excellent efficacy and tolerability, up to 50% of CML patients discontinue imatinib due to lack of …
-
Long-term effects of imatinib on cognition in chronic myeloid leukaemia
Imatinib was successfully introduced into haematology-oncology practice in 2001 and rapidly endorsed as a first line treatment for chronic myeloid leukaemia (CML) in the chronic, accelerated, and blastic phases. The survival advantage demonstrated by this target kinase inhibitor has meant that …
-
Bim Mediates Imatinib-Induced Apoptosis of Gastrointestinal Stromal Tumors: Translational Implications
… receptor tyrosine kinases KIT and PDGFR-α. Imatinib mesylate, a specific inhibitor of KIT and PDGFR-α signaling, delays progression of GIST, but is incapable of achieving cure. Thus, most patients who initially respond to imatinib therapy eventually experience tumor progression, and have …
-
Defining CP-CML patient subsets associated with poor imatinib uptake and response.
… kinase inhibitor (TKI) therapy, specifically imatinib, has dramatically improved the treatment outcome for the majority of chronic phase chronic myeloid leukaemia (CP-CML) patients. Although most patients will achieve excellent clinical (haematological, cytogenetic and molecular) responses on …
-
Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing
… stromal tumor (GIST) is effectively treated with imatinib, there are a number of clinical challenges in the optimal treatment of these patients. The plasma steady-state trough level of imatinib has been proposed to correlate with clinical outcome. Plasma imatinib level may be affected by a number …
-
Understanding the Molecular Level Interactions of Cancer Inhibitor Imatinib with Human Fibroblast Growth Factor-1
… inhibition of hFGF-1 signaling transduction by imatinib. Imatinib, a 2-phenyl amino pyrimidine derivative is a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to the intracellular pocket located within tyrosine kinases and inhibit the downstream cell proliferation events, …
-
Effetti di Sorafenib, Imatinib e CORM-A1 in un modello pre-clinico di fibrosi epatica.
… testata l’efficacia dell’inibitore del PDGF - Imatinib, dell’inibitore dell’angiogenesi - Sorafenib, somministrati da soli o in associazione, e del rilasciatore di monossido di Carbonio - CORM-A1, nel ridurre la progressione del processo fibrogenetico in un modello di danno epatico indotto in …
-
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato
L'imatinib Mesilato ha mostrato una notevole efficacia nel trattamento della Leucemia Mieloide Cronica (LMC). In ogni caso, un numero crescente di pazienti fallisce il farmaco o raggiunge risposte subottimali. Noi abbiamo voluto ricercare parametri molecolari associati ad una risposta …
-
GENERATION OF SYNTHETIC ANTIBODIES AS POTENTIAL THERAPEUTICS TO BLOCK IL3–MEDIATED INNATE IMATINIB RESISTANCE IN CHRONIC MEYLOID LEUKEMIA
… novel antibodies as therapeutics to block innate imatinib resistance in chronic myeloid leukemia (CML). Tyrosine kinase inhibitor (TKI), imatinib, is the standard therapy for CML. Although many patients respond to the conventional TKI chemotherapy, the majority relapse upon withdrawal of treatment …
-
Die Rolle der Zinkfingerproteine ZFP36L1 und ZFP36L2 und ihrer Targets in der Imatinib-Resistenz in der chronischen myeloischen Leukämie
… ZFP36L2 auf die Entstehung und Manifestation der Imatinib-Resistenz haben. Zur Untersuchung von BCR::ABL1-unabhängigen Resistenzmechanismen wurde ein in vitro-Resistenzmodell etabliert, in dem unbehandelte K-562 CML-Zellen gegen Imatinib resistent gezüchtet wurden. In diesen Imatinib-resistenten …
-
Investigating a co-operative link between TGF-β and Lyn kinase in Chronic Myeloid Leukaemia
… advent of a mechanism specific kinase inhibitor, Imatinib, targeting the constitutively active Bcr-Abl kinase has paved the way for new treatment strategies. However, resistance emerges, particularly in those in more advanced disease stages. One factor in this resistance is the presence of a …
-
Avaliação da atenção farmacêutica em pacientes que usam imatinibe em um hospital oncológico.
… atención farmacéutica en pacientes que toman imatinib en los tumores del estroma gastrointestinal en el Hospital Napoleón Laureano en João Pessoa. Methods: It is a cross - sectional, prospective, descriptive through questionnaires assessed the degree of adherence in patients with …
-
Ocorrência de eventos adversos relacionados a inibidores de tirosina quinase de primeira e segunda geração : revisão de literatura
… ts phosphorylation and resulting in cell death. Imatinib was the first inhibitor of protein tyrosine kinase BCR / ABL1 to be used and is considered the "gold standard" treatment for patients with newly diagnosed chronic myeloid leukemia. However, some pati ents can develop resistance to imatinib …
-
Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos.
… de los fármacos TKIs administrados (erlotinib, imatinib, lapatinib, pazopanib, sorafenib y sunitinib) y las consecuentes modificaciones de dosis realizadas. Material y método: estudio analítico retrospectivo en el que se han incluido 74 pacientes en tratamiento con TKIs, a los que se les ha …
-
The molecular pathogenesis of myeloproliferative neoplasms
… clones.<br/><br/>(ii) In vitro assays to predict imatinib sensitivity. Haemopoietic colony and liquid cultures were<br/>used to determine if peripheral blood or bone marrow cells from atypical MPN cases (n=200) were<br/>sensitive to imatinib. Of those that responded in one or both cultures (n=185) …
-
Mechanism of resistance to tyrosine kinase inhibitors in philadelphia-positive acute lymphblastic leukaemia (all): from genetic alterations to impaired RNA editing
… significant adverse prognostic marker. Despite imatinib has led to significant improvements in the treatment of patients with Ph+ ALL, in the majority of cases resistance developed quickly and disease progressed. Some mechanisms of resistance have been widely described but the full knowledge of …
-
Generation and Characterization of Human Blood-Brain Barrier Models for Investigating Neuropsychiatric Disorders and Tumor Metastasis
… is critical for endothelial barrier functions. Imatinib, an FDA-approved drug, inhibits Abl kinase and has been used to treat various disorders involving vascular leakages. To test if imatinib can restore the compromised iBBB, the patient’s iBBB was treated with imatinib. After treatment, both …
Page 1 of 3